文献速递肿瘤 PET/CT核素与放射性配体治疗

89Zr标记的下一代抗CD20抗体在人淋巴瘤异种移植瘤中的评价

Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts.
PubMed 文献 · J Nucl Med · 2018-01-18

研究将奥妥珠单抗、奥法妥木单抗、利妥昔单抗、托西莫单抗及人IgG用89Zr标记,在Raji伯基特淋巴瘤重度联合免疫缺陷小鼠模型中行PET/CT显像与生物分布分析,评估其肿瘤靶向能力及作为诊疗一体化或放射免疫治疗药物的潜力。

要点

  • 注射后1、3、7天所有抗CD20抗体PET/CT均见清晰肿瘤摄取,IgG肿瘤摄取极低。
  • 生物分布显示奥妥珠单抗、奥法妥木单抗、利妥昔单抗、托西莫单抗肿瘤摄取均显著高于IgG(P<0.005)。
  • 托西莫单抗脾摄取显著高于其他抗体(P<0.001)。

核心结论

  • 89Zr标记的奥妥珠单抗和奥法妥木单抗在肿瘤内定位不劣于或优于曾用于B细胞淋巴瘤放射免疫治疗的利妥昔单抗和托西莫单抗。
  • 奥妥珠单抗和奥法妥木单抗均具有重复给药的潜力。

研究设计与样本

  • 临床前小鼠模型研究:在重度联合免疫缺陷小鼠中建立Raji伯基特淋巴瘤异种移植瘤。
  • 将奥妥珠单抗、奥法妥木单抗、利妥昔单抗、托西莫单抗及人IgG用89Zr标记。
  • 可触及肿瘤的小鼠(n=4–9)注射上述89Zr标记抗体,于注射后1、3、7天行小动物PET/CT显像,随后处死行生物分布分析。

主要发现

  • 注射后1、3、7天,所有抗CD20抗体在PET/CT上均显示清晰的肿瘤摄取,而IgG肿瘤摄取极低。
  • 生物分布显示肿瘤摄取:奥妥珠单抗41.4±7.6 %ID/g、奥法妥木单抗32.6±17.5 %ID/g、利妥昔单抗28.6±7.6 %ID/g、托西莫单抗28.0±6.5 %ID/g,均显著高于IgG的7.2±1.2 %ID/g(P<0.005)。
  • 托西莫单抗脾摄取为186.4±49.7 %ID/g,显著高于其他抗体(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting redosing. The Food and Drug Administration recently approved 2 unlabeled anti-CD20 monoclonal antibodies, obinutuzumab and ofatumumab, termed next generation as they are humanized (obinutuzumab) or fully human (ofatumumab), thus potentially allowing a greater potential for redosing than with previous-generation anti-CD20 antibodies, including rituximab (chimeric) and tositumomab (murine), which contain more murine peptide sequences. We prepared 89Zr-ofatumumab and 89Zr-obinituzumab and assessed their tumor targeting by PET/CT imaging and their biodistribution in a preclinical mouse model with CD20 xenografts to determine whether these antibodies have potential as theranostics or for radioimmunotherapy. Methods: Obinutuzumab, ofatumumab, rituximab, tositumomab, and human IgG (as control) were radiolabeled with 89Zr. Raji Burkitt lymphoma xenografts were established in severe combined immunodeficient mice. Mice with palpable tumors (n = 4-9) were injected with 89Zr-obinutuzumab, 89Zr-ofatumumab, 89Zr-rituximab, 89Zr-tositumomab, or 89Zr-IgG, with small-animal PET/CT images acquired at 1, 3, and 7 d after injection, and then sacrificed for biodistribution analyses. Results: At 1, 3, and 7 d after injection, all anti-CD20 antibodies showed clear tumor uptake on PET/CT, with minimal tumor uptake of IgG. Biodistribution data showed significantly (P < 0.005) higher tumor uptake for obinutuzumab (41.4 ± 7.6 percentage injected dose [%ID]/g), ofatumumab (32.6 ± 17.5 %ID/g), rituximab (28.6 ± 7.6 %ID/g), and tositumomab (28.0 ± 6.5 %ID/g) than IgG (7.2 ± 1.2 %ID/g). Tositumomab had much higher splenic uptake (186.4 ± 49.7 %ID/g, P < 0.001) than the other antibodies. Conclusion:89Zr-labeled obinutuzumab and ofatumumab localized to tumor as well as or better than labeled rituximab and tositumomab, 2 monoclonal antibodies that have been used previously in B-cell lymphoma radioimmunotherapy, and both obinutuzumab and ofatumumab have the potential for repeated dosing.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yoon JT, Longtine MS, Marquez-Nostra BV, et al. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts. J Nucl Med. 2018. PMID: 29348316. doi:10.2967/jnumed.117.203299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。